Dr. Thomas Schinecker, the current CEO of Roche Group, stands as a seasoned Austrian/German executive with a remarkable trajectory in the global healthcare industry. His extensive experience spans diverse regions worldwide, including Asia, the USA, and several European countries, shaping him both personally and professionally.
Having joined Roche in 2003, Schinecker underwent a comprehensive management development program across multiple regions, exhibiting his adaptability and resilience. His journey within the company included significant roles in diagnostics, marketing, and sales, marking him as a versatile leader within the organization.
In 2018, Schinecker joined Roche's global diagnostics team and assumed the role of Global Head of Centralized & PoC Diagnostics, emphasizing the critical role diagnostics play in addressing healthcare challenges.
A pivotal moment in Schinecker’s career came when he assumed the role of CEO at Roche Diagnostics Basel in 2019, showcasing visionary leadership and strategic acumen. Later, he became the General Manager of Roche Diagnostics in Germany, further solidifying his impact within the company.
Under his leadership, Roche Diagnostics experienced significant sales growth, with revenues reaching an impressive $19.4 billion, a 29% increase. His commitment to advancing healthcare solutions and addressing challenges such as cancer and infectious diseases has been evident throughout his career.
In December 2022, Schinecker expanded his responsibilities by taking on the role of CEO of Roche Pharma, succeeding Severin Schwan. His transition to this role signified the company's confidence in his strategic vision and leadership capabilities.
With a Ph.D. in Molecular Biology from New York University, Schinecker brings a unique combination of scientific expertise and business acumen to the forefront of the company's leadership. As a visionary leader, he envisions harnessing the power of diagnostics to tackle healthcare's greatest challenges, emphasizing the role of cutting-edge technologies and solutions.
Additionally, Schinecker’s commitment extends to fostering collaboration and partnerships to drive innovation in healthcare. He emphasizes the importance of working closely with stakeholders to advance diagnostics, ensuring equitable access to high-quality healthcare services globally.
In leading Roche's transformative healthcare journey, Schinecker's clear and forward-thinking vision positions him as a highly respected and influential figure in the industry. As the company continues to innovate under his guidance, the impact on patient care and the healthcare landscape is expected to be substantial.